Sphera Funds Management’s Oric Pharmaceuticals ORIC Stock Holding History

Sphera Funds Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.81M	Sell	537,628 -466,750	-46%	-$5.3M	1.08%	31
2025 Q4	$8.22M	Buy	1,004,378 +572,685	+133%	+$6.59M	1.59%	17
2025 Q3	$5.18M	Buy	431,693 +37,000	+9%	+$389K	1.09%	31
2025 Q2	$4.01M	Buy	394,693 +159,859	+68%	+$1.07M	0.94%	39
2025 Q1	$1.31M	Sell	234,834 -38,379	-14%	-$336K	0.3%	83
2024 Q4	$2.2M	Buy	273,213 +144,817	+113%	+$1.33M	0.4%	79
2024 Q3	$1.32M	Buy	+128,396	New	+$1.27M	0.21%	97
2024 Q1	–	Sell	-126,800	Closed	-$1.17M	–	116
2023 Q4	$1.17M	Buy	+126,800	New	+$917K	0.19%	85
2021 Q2	–	Sell	-169,900	Closed	-$4.16M	–	161
2021 Q1	$4.16M	Sell	169,900 -12,300	-7%	-$389K	0.32%	80
2020 Q4	$6.17M	Buy	+182,200	New	+$5.23M	0.55%	56

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sphera Funds Management's ORIC Position: Q1 2026 in Review

Sphera Funds Management reduced its Oric Pharmaceuticals (ORIC) stake by 46% in Q1 2026, selling an estimated $5.3M and leaving 537,628 shares worth $6.81M. The position accounts for 1.08% of the portfolio, ranked #31.

Sphera Funds Management first reported a position in ORIC in Q4 2020 and has held it in 10 quarters since. The position peaked at $8.22M in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Sphera Funds Management held 537,628 shares of Oric Pharmaceuticals worth $6.81M as of Q1 2026.
Sphera Funds Management sold 466,750 Oric Pharmaceuticals shares in Q1 2026, an estimated $5.3M.
Oric Pharmaceuticals made up 1.08% of Sphera Funds Management's portfolio in Q1 2026, its #31 holding.
Sphera Funds Management first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 10 quarters since.
Sphera Funds Management's Oric Pharmaceuticals position peaked at $8.22M in Q4 2025.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.